UA80754C2 - Diphenyl azetidinones, medicaments containing said compound and use of the latter - Google Patents

Diphenyl azetidinones, medicaments containing said compound and use of the latter Download PDF

Info

Publication number: UA80754C2
Authority: UA; Ukraine
Prior art keywords: agonists; formula; inhibitors; compound; acid
Prior art date: 2003-04-01

Application number

UAA200510204A

Other languages

English (en)

Ukrainian (uk)

Inventor

Gerhardt Jene

Wendelin Frick

Andreas Lindenschmidt

Stephanie Flor

Hubert Heuer

Hans-Ludwig Sheffer

Werner Kramer

Heiner Glombik

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-01

Filing date

2004-03-16

Publication date

2007-10-25

2004-03-16 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2007-10-25 Publication of UA80754C2 publication Critical patent/UA80754C2/uk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 119
VDOXIAUNJCHYRC-UHFFFAOYSA-N 1,3-diphenylazetidin-2-one Chemical class O=C1C(C=2C=CC=CC=2)CN1C1=CC=CC=C1 VDOXIAUNJCHYRC-UHFFFAOYSA-N 0.000 title abstract description 4
239000003814 drug Substances 0.000 title abstract description 4
238000000034 method Methods 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 11
239000000556 agonist Substances 0.000 claims description 35
239000003112 inhibitor Substances 0.000 claims description 24
239000013543 active substance Substances 0.000 claims description 17
-1 lipase inhibitors Substances 0.000 claims description 16
239000005557 antagonist Substances 0.000 claims description 13
229940088623 biologically active substance Drugs 0.000 claims description 13
229940126601 medicinal product Drugs 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 9
102000004877 Insulin Human genes 0.000 claims description 8
108090001061 Insulin Proteins 0.000 claims description 8
229940100389 Sulfonylurea Drugs 0.000 claims description 6
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 5
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 4
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
239000003613 bile acid Substances 0.000 claims description 4
235000012000 cholesterol Nutrition 0.000 claims description 4
239000000122 growth hormone Substances 0.000 claims description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
101001090074 Homo sapiens Small nuclear protein PRAC1 Proteins 0.000 claims description 3
102000016267 Leptin Human genes 0.000 claims description 3
108010092277 Leptin Proteins 0.000 claims description 3
239000004367 Lipase Substances 0.000 claims description 3
102000004257 Potassium Channel Human genes 0.000 claims description 3
102100034766 Small nuclear protein PRAC1 Human genes 0.000 claims description 3
229940123464 Thiazolidinedione Drugs 0.000 claims description 3
108010059705 Urocortins Proteins 0.000 claims description 3
102000005630 Urocortins Human genes 0.000 claims description 3
229940125708 antidiabetic agent Drugs 0.000 claims description 3
239000003472 antidiabetic agent Substances 0.000 claims description 3
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 3
230000001419 dependent effect Effects 0.000 claims description 3
230000002218 hypoglycaemic effect Effects 0.000 claims description 3
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 3
229940039781 leptin Drugs 0.000 claims description 3
229950004994 meglitinide Drugs 0.000 claims description 3
108020001213 potassium channel Proteins 0.000 claims description 3
239000000777 urocortin Substances 0.000 claims description 3
102000004146 ATP citrate synthases Human genes 0.000 claims description 2
108090000662 ATP citrate synthases Proteins 0.000 claims description 2
229940123208 Biguanide Drugs 0.000 claims description 2
108010051479 Bombesin Proteins 0.000 claims description 2
102000013585 Bombesin Human genes 0.000 claims description 2
102100033868 Cannabinoid receptor 1 Human genes 0.000 claims description 2
101710187010 Cannabinoid receptor 1 Proteins 0.000 claims description 2
101800002068 Galanin Proteins 0.000 claims description 2
102000019432 Galanin Human genes 0.000 claims description 2
102000018997 Growth Hormone Human genes 0.000 claims description 2
108010051696 Growth Hormone Proteins 0.000 claims description 2
208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
102000004882 Lipase Human genes 0.000 claims description 2
108090001060 Lipase Proteins 0.000 claims description 2
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims description 2
108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims description 2
102000002512 Orexin Human genes 0.000 claims description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
239000003392 amylase inhibitor Substances 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 2
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 2
229960002802 bromocriptine Drugs 0.000 claims description 2
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 2
229940125753 fibrate Drugs 0.000 claims description 2
239000004026 insulin derivative Substances 0.000 claims description 2
235000019421 lipase Nutrition 0.000 claims description 2
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 2
230000002474 noradrenergic effect Effects 0.000 claims description 2
108060005714 orexin Proteins 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
108091006084 receptor activators Proteins 0.000 claims description 2
229940076279 serotonin Drugs 0.000 claims description 2
239000000952 serotonin receptor agonist Substances 0.000 claims description 2
239000003772 serotonin uptake inhibitor Substances 0.000 claims description 2
230000002295 serotoninergic effect Effects 0.000 claims description 2
239000004059 squalene synthase inhibitor Substances 0.000 claims description 2
150000001467 thiazolidinediones Chemical class 0.000 claims description 2
102000003390 tumor necrosis factor Human genes 0.000 claims description 2
239000013067 intermediate product Substances 0.000 claims 3
102000004895 Lipoproteins Human genes 0.000 claims 2
108090001030 Lipoproteins Proteins 0.000 claims 2
230000037356 lipid metabolism Effects 0.000 claims 2
235000010469 Glycine max Nutrition 0.000 claims 1
244000068988 Glycine max Species 0.000 claims 1
206010022489 Insulin Resistance Diseases 0.000 claims 1
229940127470 Lipase Inhibitors Drugs 0.000 claims 1
229940124757 MC-4 agonist Drugs 0.000 claims 1
229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 claims 1
239000000883 anti-obesity agent Substances 0.000 claims 1
229940125710 antiobesity agent Drugs 0.000 claims 1
239000002830 appetite depressant Substances 0.000 claims 1
150000004283 biguanides Chemical class 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
239000002464 receptor antagonist Substances 0.000 claims 1
229940044551 receptor antagonist Drugs 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000000055 hyoplipidemic effect Effects 0.000 abstract 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 14
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 13
WMRCTEPOPAZMMN-UHFFFAOYSA-N 2-undecylpropanedioic acid Chemical compound CCCCCCCCCCCC(C(O)=O)C(O)=O WMRCTEPOPAZMMN-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
239000000126 substance Substances 0.000 description 9
230000003993 interaction Effects 0.000 description 7
238000004949 mass spectrometry Methods 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
150000001408 amides Chemical class 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
229940125396 insulin Drugs 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
239000003826 tablet Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000009471 action Effects 0.000 description 5
238000009739 binding Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000012043 crude product Substances 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
229960003105 metformin Drugs 0.000 description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000000047 product Substances 0.000 description 4
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001718 carbodiimides Chemical class 0.000 description 3
230000001906 cholesterol absorption Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
239000000843 powder Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
229960002354 repaglinide Drugs 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1h-naphthalen-2-one Chemical compound C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229960002632 acarbose Drugs 0.000 description 2
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
XHLHPRDBBAGVEG-UHFFFAOYSA-N alpha-Tetralone Natural products C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
235000021152 breakfast Nutrition 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960004597 dexfenfluramine Drugs 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000029142 excretion Effects 0.000 description 2
230000002550 fecal effect Effects 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
229960004580 glibenclamide Drugs 0.000 description 2
229960004346 glimepiride Drugs 0.000 description 2
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
229960001381 glipizide Drugs 0.000 description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229960004844 lovastatin Drugs 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000000465 moulding Methods 0.000 description 2
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
229960001243 orlistat Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
229960005095 pioglitazone Drugs 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
229960005371 tolbutamide Drugs 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
IFPMZBBHBZQTOV-UHFFFAOYSA-N 1,3,5-trinitro-2-(2,4,6-trinitrophenyl)-4-[2,4,6-trinitro-3-(2,4,6-trinitrophenyl)phenyl]benzene Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C=2C(=C(C=3C(=CC(=CC=3[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)C(=CC=2[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)=C1[N+]([O-])=O IFPMZBBHBZQTOV-UHFFFAOYSA-N 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
MHCKTCPQIUFRLF-UHFFFAOYSA-N 1-azaniumyl-1,2,3,4-tetrahydronaphthalene-2-carboxylate Chemical compound C1=CC=C2C(N)C(C(O)=O)CCC2=C1 MHCKTCPQIUFRLF-UHFFFAOYSA-N 0.000 description 1
102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 1
VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
244000005894 Albizia lebbeck Species 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
108010018763 Biotin carboxylase Proteins 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
240000008886 Ceratonia siliqua Species 0.000 description 1
235000013912 Ceratonia siliqua Nutrition 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
229920002905 Colesevelam Polymers 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
102000004366 Glucosidases Human genes 0.000 description 1
108010056771 Glucosidases Proteins 0.000 description 1
102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
BCRDPGDQDVFPNE-NSHGMRRFSA-N Hervin Natural products COC(=O)[C@H](CO)[C@H]1C[C@@H]2N(CCc3c2[nH]c4cc(OC)ccc34)CC1=CC BCRDPGDQDVFPNE-NSHGMRRFSA-N 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
229940086609 Lipase inhibitor Drugs 0.000 description 1
108010013563 Lipoprotein Lipase Proteins 0.000 description 1
102100022119 Lipoprotein lipase Human genes 0.000 description 1
102000057248 Lipoprotein(a) Human genes 0.000 description 1
108010033266 Lipoprotein(a) Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical group N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
229940127315 Potassium Channel Openers Drugs 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
235000011449 Rosa Nutrition 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
241001415849 Strigiformes Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000145297 Vanni Species 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
230000002402 anti-lipaemic effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
235000015241 bacon Nutrition 0.000 description 1
235000015173 baked goods and baking mixes Nutrition 0.000 description 1
239000002585 base Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229960005110 cerivastatin Drugs 0.000 description 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
229950009226 ciglitazone Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960001152 colesevelam Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
229960000815 ezetimibe Drugs 0.000 description 1
229960001582 fenfluramine Drugs 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000004116 glycogenolysis Effects 0.000 description 1
235000014168 granola/muesli bars Nutrition 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
230000036541 health Effects 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229950005809 implitapide Drugs 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229940028435 intralipid Drugs 0.000 description 1
229940045996 isethionic acid Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229940099563 lactobionic acid Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960000299 mazindol Drugs 0.000 description 1
239000002609 medium Substances 0.000 description 1
ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960001110 miglitol Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
YDCVQGAUCOROHB-UHFFFAOYSA-N oxadiazolidine-4,5-dione Chemical class O=C1NNOC1=O YDCVQGAUCOROHB-UHFFFAOYSA-N 0.000 description 1
VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 1
229950005482 pamaqueside Drugs 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
229960003562 phentermine Drugs 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
238000003825 pressing Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229960000672 rosuvastatin Drugs 0.000 description 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229950004437 tiqueside Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

UAA200510204A 2003-04-01 2004-03-16 Diphenyl azetidinones, medicaments containing said compound and use of the latter UA80754C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10314610A DE10314610A1 (de)	2003-04-01	2003-04-01	Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
PCT/EP2004/002690 WO2004087655A1 (de)	2003-04-01	2004-03-16	Neues diphenylazetidinon mit verbesserten physiologischen eigenschaften, verfahren zu dessen herstellung, diese verbindungen enthaltende arzneimittel und dessen verwendung

Publications (1)

Publication Number	Publication Date
UA80754C2 true UA80754C2 (en)	2007-10-25

Family

ID=33103147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200510204A UA80754C2 (en)	2003-04-01	2004-03-16	Diphenyl azetidinones, medicaments containing said compound and use of the latter

Country Status (43)

Country	Link
US (2)	US7205290B2 (zh)
EP (2)	EP1613589B1 (zh)
JP (1)	JP2006522040A (zh)
KR (1)	KR20050119180A (zh)
CN (2)	CN101139306A (zh)
AR (1)	AR043783A1 (zh)
AT (2)	ATE386020T1 (zh)
AU (1)	AU2004226287B2 (zh)
BR (1)	BRPI0408920A (zh)
CA (1)	CA2520689A1 (zh)
CL (1)	CL43489B (zh)
CR (1)	CR7995A (zh)
CY (2)	CY1107398T1 (zh)
DE (3)	DE10314610A1 (zh)
DK (2)	DK1862455T3 (zh)
EC (1)	ECSP056071A (zh)
ES (2)	ES2322876T3 (zh)
GT (1)	GT200400058A (zh)
HN (1)	HN2004000109A (zh)
HR (1)	HRP20050870A2 (zh)
JO (1)	JO2493B1 (zh)
MA (1)	MA27753A1 (zh)
ME (1)	MEP41408A (zh)
MX (1)	MXPA05010128A (zh)
MY (1)	MY136269A (zh)
NI (1)	NI200500164A (zh)
NO (1)	NO20055001L (zh)
NZ (1)	NZ542751A (zh)
PA (1)	PA8599401A1 (zh)
PE (1)	PE20050011A1 (zh)
PL (2)	PL1613589T3 (zh)
PT (2)	PT1862455E (zh)
RS (1)	RS51146B (zh)
RU (1)	RU2334737C2 (zh)
SA (1)	SA04250154B1 (zh)
SI (2)	SI1862455T1 (zh)
SV (1)	SV2004001756A (zh)
TN (1)	TNSN05244A1 (zh)
TW (1)	TW200504009A (zh)
UA (1)	UA80754C2 (zh)
UY (1)	UY28253A1 (zh)
WO (1)	WO2004087655A1 (zh)
ZA (1)	ZA200506708B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1217927C (zh) *	2000-12-21	2005-09-07	阿文蒂斯药物德国有限公司	新的1,2－二苯基氮杂环丁烷酮、其制备方法、含有所述化合物的药物及其在治疗脂质代谢病症中的应用
WO2007001975A1 (en)	2005-06-20	2007-01-04	Schering Corporation	Piperidine derivatives useful as histamine h3 antagonists
US7067689B1 (en)	2005-07-08	2006-06-27	Microbia, Inc.	Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
DE102007029612A1 (de) *	2007-06-27	2009-01-08	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
US20080319221A1 (en) *	2007-06-22	2008-12-25	Bernd Junker	Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) *	2007-06-22	2008-12-25	Andreas Haubrich	Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) *	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
AU2009212314C1 (en) *	2008-02-05	2014-05-08	Harbor Biosciences, Inc.	Pharmaceutical solid state forms
DE102008059772A1 (de)	2008-12-01	2010-06-02	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung eines Diphenylazetidinons
WO2009112203A1 (de) *	2008-03-14	2009-09-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur herstellung eines diphenylazetidinons
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683700B1 (de)	2011-03-08	2015-02-18	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10426480B2 (en) *	2015-04-29	2019-10-01	Covidien Lp	Cutting ring assembly with rigid cutting member

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US576470A (en) *		1897-02-02		Boiler-furnace
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5756740A (en) *	1992-04-08	1998-05-26	Eastman Kodak Company	Process for the preparation of binary sensitizing dyes
FR2713225B1 (fr)	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) *	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997026265A1 (en)	1996-01-17	1997-07-24	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
EP1826216A1 (en)	1996-08-30	2007-08-29	Novo Nordisk A/S	Glp-1 derivatives
US5756470A (en) *	1996-10-29	1998-05-26	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt)	1997-07-16	2000-09-12	Novo Nordisk As	Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ATE266659T1 (de)	1998-03-12	2004-05-15	Teijin Ltd	Benzofurylpyron-derivate
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
CZ295889B6 (cs)	1998-12-07	2005-11-16	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající arginin na pozicích 26 a 34, jejich použití a farmaceutické prostředky je obsahující
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
CN1331862C (zh)	1999-04-28	2007-08-15	萨诺费－阿文蒂斯德国有限公司	作为ppar受体配体的二芳基酸衍生物
KR100693771B1 (ko)	1999-04-28	2007-03-12	사노피-아벤티스 도이칠란트 게엠베하	Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
EP1194146B1 (en)	1999-06-18	2006-07-19	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
WO2001009111A1 (en)	1999-07-29	2001-02-08	Eli Lilly And Company	Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
SK2682002A3 (en) *	1999-09-01	2002-07-02	Aventis Pharma Gmbh	Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
JP2003523396A (ja)	2000-02-25	2003-08-05	ノボノルディスクアクティーゼルスカブ	ベータ細胞変性の抑制
AU5257401A (en)	2000-04-28	2001-11-12	Asahi Chemical Ind	Novel bicyclic compounds
EP1280777B1 (en)	2000-05-11	2005-11-23	Bristol-Myers Squibb Company	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SE0001899D0 (sv)	2000-05-22	2000-05-22	Pharmacia & Upjohn Ab	New compounds
HUP0004741A2 (hu)	2000-11-28	2002-12-28	Sanofi-Synthelabo	Kémiai eljárás tiazolszármazékok előállítására és új intermedier
CN1217927C (zh) *	2000-12-21	2005-09-07	阿文蒂斯药物德国有限公司	新的1,2－二苯基氮杂环丁烷酮、其制备方法、含有所述化合物的药物及其在治疗脂质代谢病症中的应用
DE10139416A1 (de)	2001-08-17	2003-03-06	Aventis Pharma Gmbh	Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6884812B2 (en) *	2001-08-31	2005-04-26	Aventis Pharma Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
ATE347890T1 (de) *	2001-08-31	2007-01-15	Sanofi Aventis Deutschland	Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren
US7176194B2 (en) *	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) *	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds

2003
- 2003-04-01 DE DE10314610A patent/DE10314610A1/de not_active Withdrawn
2004
- 2004-02-24 JO JO200418A patent/JO2493B1/en active
- 2004-03-16 SI SI200431100T patent/SI1862455T1/sl unknown
- 2004-03-16 DK DK07016889T patent/DK1862455T3/da active
- 2004-03-16 EP EP04720854A patent/EP1613589B1/de not_active Expired - Lifetime
- 2004-03-16 NZ NZ542751A patent/NZ542751A/en unknown
- 2004-03-16 DE DE502004009059T patent/DE502004009059D1/de not_active Expired - Lifetime
- 2004-03-16 PT PT07016889T patent/PT1862455E/pt unknown
- 2004-03-16 AT AT04720854T patent/ATE386020T1/de not_active IP Right Cessation
- 2004-03-16 JP JP2006504695A patent/JP2006522040A/ja active Pending
- 2004-03-16 UA UAA200510204A patent/UA80754C2/uk unknown
- 2004-03-16 ME MEP-414/08A patent/MEP41408A/xx unknown
- 2004-03-16 PT PT04720854T patent/PT1613589E/pt unknown
- 2004-03-16 PL PL04720854T patent/PL1613589T3/pl unknown
- 2004-03-16 DE DE502004006195T patent/DE502004006195D1/de not_active Expired - Lifetime
- 2004-03-16 HR HR20050870A patent/HRP20050870A2/xx not_active Application Discontinuation
- 2004-03-16 BR BRPI0408920-0A patent/BRPI0408920A/pt not_active IP Right Cessation
- 2004-03-16 KR KR1020057018705A patent/KR20050119180A/ko not_active Ceased
- 2004-03-16 PL PL07016889T patent/PL1862455T3/pl unknown
- 2004-03-16 CN CNA2007101491852A patent/CN101139306A/zh active Pending
- 2004-03-16 AT AT07016889T patent/ATE423766T1/de not_active IP Right Cessation
- 2004-03-16 MX MXPA05010128A patent/MXPA05010128A/es active IP Right Grant
- 2004-03-16 ES ES07016889T patent/ES2322876T3/es not_active Expired - Lifetime
- 2004-03-16 SI SI200430681T patent/SI1613589T1/sl unknown
- 2004-03-16 DK DK04720854T patent/DK1613589T3/da active
- 2004-03-16 RS YUP-2005/0719A patent/RS51146B/sr unknown
- 2004-03-16 EP EP07016889A patent/EP1862455B1/de not_active Expired - Lifetime
- 2004-03-16 ES ES04720854T patent/ES2298731T3/es not_active Expired - Lifetime
- 2004-03-16 AU AU2004226287A patent/AU2004226287B2/en not_active Ceased
- 2004-03-16 RU RU2005133631/04A patent/RU2334737C2/ru not_active IP Right Cessation
- 2004-03-16 CA CA002520689A patent/CA2520689A1/en not_active Abandoned
- 2004-03-16 CN CNB2004800084976A patent/CN100361970C/zh not_active Expired - Fee Related
- 2004-03-16 WO PCT/EP2004/002690 patent/WO2004087655A1/de not_active Ceased
- 2004-03-29 HN HN2004000109A patent/HN2004000109A/es unknown
- 2004-03-29 PE PE2004000330A patent/PE20050011A1/es not_active Application Discontinuation
- 2004-03-30 TW TW093108581A patent/TW200504009A/zh unknown
- 2004-03-30 AR ARP040101052A patent/AR043783A1/es unknown
- 2004-03-30 PA PA20048599401A patent/PA8599401A1/es unknown
- 2004-03-31 SV SV2004001756A patent/SV2004001756A/es not_active Application Discontinuation
- 2004-03-31 US US10/813,954 patent/US7205290B2/en not_active Expired - Fee Related
- 2004-03-31 UY UY28253A patent/UY28253A1/es unknown
- 2004-03-31 MY MYPI20041165A patent/MY136269A/en unknown
- 2004-03-31 GT GT200400058A patent/GT200400058A/es unknown
- 2004-04-01 CL CL200400708A patent/CL43489B/es active
- 2004-06-09 SA SA04250154A patent/SA04250154B1/ar unknown
2005
- 2005-08-22 ZA ZA200506708A patent/ZA200506708B/en unknown
- 2005-09-19 CR CR7995A patent/CR7995A/es unknown
- 2005-09-22 NI NI200500164A patent/NI200500164A/es unknown
- 2005-09-30 TN TNP2005000244A patent/TNSN05244A1/en unknown
- 2005-09-30 EC EC2005006071A patent/ECSP056071A/es unknown
- 2005-09-30 MA MA28529A patent/MA27753A1/fr unknown
- 2005-10-27 NO NO20055001A patent/NO20055001L/no not_active Application Discontinuation
2007
- 2007-03-26 US US11/690,993 patent/US7772429B2/en not_active Expired - Fee Related
2008
- 2008-04-17 CY CY20081100429T patent/CY1107398T1/el unknown
2009
- 2009-05-11 CY CY20091100503T patent/CY1109055T1/el unknown

Also Published As

Publication number	Publication date
MY136269A (en)	2008-09-30
EP1862455A3 (de)	2007-12-12
HRP20050870A2 (en)	2006-10-31
EP1613589B1 (de)	2008-02-13
CA2520689A1 (en)	2004-10-14
US20070197498A1 (en)	2007-08-23
CY1107398T1 (el)	2012-12-19
EP1862455A2 (de)	2007-12-05
RS20050719A (sr)	2008-04-04
PL1862455T3 (pl)	2009-07-31
US7205290B2 (en)	2007-04-17
ES2322876T3 (es)	2009-06-30
HK1087697A1 (zh)	2006-10-20
AU2004226287A1 (en)	2004-10-14
SV2004001756A (es)	2004-11-18
JO2493B1 (en)	2009-10-05
KR20050119180A (ko)	2005-12-20
SI1613589T1 (sl)	2008-06-30
PL1613589T3 (pl)	2008-07-31
MA27753A1 (fr)	2006-02-01
AR043783A1 (es)	2005-08-10
CN101139306A (zh)	2008-03-12
RS51146B (sr)	2010-10-31
NZ542751A (en)	2007-05-31
PT1862455E (pt)	2009-04-23
US7772429B2 (en)	2010-08-10
DK1613589T3 (da)	2008-06-09
US20050020563A1 (en)	2005-01-27
CN1768034A (zh)	2006-05-03
CY1109055T1 (el)	2014-07-02
PT1613589E (pt)	2008-03-27
DE10314610A1 (de)	2004-11-04
MXPA05010128A (es)	2005-11-16
EP1613589A1 (de)	2006-01-11
PE20050011A1 (es)	2005-02-28
ES2298731T3 (es)	2008-05-16
MEP41408A (en)	2011-02-10
NO20055001L (no)	2005-10-27
CL43489B (es)	2005-01-21
UY28253A1 (es)	2004-11-08
TW200504009A (en)	2005-02-01
CR7995A (es)	2006-09-22
SI1862455T1 (sl)	2009-06-30
ECSP056071A (es)	2006-01-27
NI200500164A (es)	2006-01-11
DK1862455T3 (da)	2009-06-02
PA8599401A1 (es)	2004-10-08
RU2334737C2 (ru)	2008-09-27
GT200400058A (es)	2004-11-10
SA04250154B1 (ar)	2007-10-29
DE502004006195D1 (de)	2008-03-27
WO2004087655A1 (de)	2004-10-14
CN100361970C (zh)	2008-01-16
TNSN05244A1 (en)	2007-06-11
BRPI0408920A (pt)	2006-03-28
ZA200506708B (en)	2007-01-31
HN2004000109A (es)	2008-02-21
ATE423766T1 (de)	2009-03-15
ATE386020T1 (de)	2008-03-15
DE502004009059D1 (de)	2009-04-09
EP1862455B1 (de)	2009-02-25
RU2005133631A (ru)	2006-03-10
AU2004226287B2 (en)	2010-03-18
JP2006522040A (ja)	2006-09-28

Publication	Publication Date	Title
UA80754C2 (en)	2007-10-25	Diphenyl azetidinones, medicaments containing said compound and use of the latter
EP1345895B1 (de)	2006-12-27	Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
US6703386B2 (en)	2004-03-09	Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use
RU2287522C2 (ru)	2006-11-20	Замещенные кислотными группами дифенилазетидиноны, способ их получения, содержащие эти соединения лекарственные средства и их применение
AU2003238209B2 (en)	2009-01-22	Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
US20040077623A1 (en)	2004-04-22	Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
RU2286985C2 (ru)	2006-11-10	Новые 1,2-дифенилазетидиноны, их применение для лечения нарушений липидного обмена, лекарственное средство и способ его получения
RU2282628C2 (ru)	2006-08-27	Производные дифенилазетидинона, фармацевтическая композиция на их основе и способ ее получения
HK1087697B (zh)	2008-05-02	具有改善的生理学性质的新的二苯基2-吖丁啶酮、其制备方法、包含所述化合物的药物和所述化合物的用途
HK1115861A (zh)	2008-12-12	具有改善的生理学性质的新的二苯基2-吖丁啶酮、其制备方法、包含所述化合物的药物和所述化合物的用途